A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...

Hereditary hemorrhagic telangiectasia (HHT) can cause recurrent, severe epistaxis, as well as anemia and reduced quality of life. The disease remains without licensed therapies worldwide. In this ...

SAN DIEGO -- In a randomized trial, pomalidomide (Pomalyst) significantly reduced severe nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT), a condition with no approved therapy.

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...

Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting one in 3,800 persons. HHT's hallmark symptom is chronic nosebleeds, which often ...

Preliminary results indicate HHT patients are significantly impacted by bleeding events, with consistency in severity reporting at months one and three of the study Final study analysis will inform ...

Study conducted in partnership with Cure HHT will inform future clinical trials and treatment options for people living with HHT Company recently progressed DIAG723 into IND-enabling studies for HHT ...

Despite the considerable disease burden associated with hereditary hemorrhagic telangiectasia, no therapies are licensed for treatment. In a proof-of-concept, placebo-controlled trial, the ...

Strategically developed to promote the care team’s awareness of HHT and galvanize optimization of HHT-associated IDA management, this series of Ace the Case sessions will highlight key teaching points ...

WATERTOWN, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe ...